<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31899540</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.</ArticleTitle><Pagination><StartPage>156</StartPage><EndPage>166</EndPage><MedlinePgn>156-166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.26801</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder with complex biology and significant clinical heterogeneity. Many preclinical and early phase ALS clinical trials have yielded promising results that could not be replicated in larger phase 3 confirmatory trials. One reason for the lack of reproducibility may be ALS biological and clinical heterogeneity. Therefore, in this review, we explore sources of ALS heterogeneity that may reduce statistical power to evaluate efficacy in ALS trials. We also review efforts to manage clinical heterogeneity, including use of validated disease outcome measures, predictive biomarkers of disease progression, and individual clinical risk stratification. We propose that personalized prognostic models with use of predictive biomarkers may identify patients with ALS for whom a specific therapeutic strategy may be expected to be more successful. Finally, the rapid application of emerging clinical and biomarker strategies may reduce heterogeneity, increase trial efficiency, and, in turn, accelerate ALS drug development.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Muscle &amp; Nerve published by Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>University of California, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Healey Center at Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windebank</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Robert H. Baloh, Cedars-Sinai Medical Center, California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Brainstorm Cell Therapeutics, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gothelf</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brainstorm Cell Therapeutics, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebovits</LastName><ForeName>Chaim</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Brainstorm Cell Therapeutics, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Healey Center at Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073537" MajorTopicYN="Y">Biological Variation, Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076604" MajorTopicYN="N">Physical Functional Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">disease heterogeneity</Keyword><Keyword MajorTopicYN="N">enrichment strategies</Keyword><Keyword MajorTopicYN="N">outcome measures</Keyword></KeywordList><CoiStatement>Namita Goyal has received research support from Amylyx Therapeutics, Brainstorm Cell Therapeutics, Cytokinetics, Orphazyme, and Orion and provided advisory board support for Cytokinetics, Biogen, Acceleron, and MT Pharma. James Berry has been a consultant for Clene Nanomedicine, Orion Pharmaceuticals, and Denali Therapeutics and has received research support from Anelixis Therapeutics, Amylyx Therapeutics, Brainstorm Cell Therapeutics, Biogen, Cytokinetics, MT Pharma of America, and Neuraltus Pharmaceuticals. Anthony Windebank has received support for conduct of clinical trials from BrainStorm Cell Therapeutics. Nathan Staff serves as site investigator for clinical trials funded by Brainstorm Cell Therapeutics and Orion Pharmaceuticals. Nicholas Maragakis serves on scientific advisory boards for Brainstorm Cell Therapeutics, Clene Nanomedicine and Orion Pharma. Leonard H. van den Berg serves on scientific advisory boards for the Biogen, Cytokinetics, Orion, and Sarepta. Angela Genge serves on the advisory boards of Avexis, Alexion, AL&#x2010;S Pharma, Biogen, Brainstorm, Akcea, Cytokinetics, Sanofi, Mitsubishi, and Novartis. Robert Miller has received research support from BrainStorm Cell Therapeutics, Cytokinetics, Amylyx, Neuraltus, Bioelectron and provided advisory board support for Cytokinetics, AveXis, Neuraltus and MT Pharma. Merit Cudkowicz has been a consultant for Biohaven, Biogen, Takeda, Avexis, and Revalesio and chaired DSMB for Lilly. Ralph Kern, Yael Gothelf and Chaim Lebovits are Brainstorm Cell Therapeutics employees. Robert Baloh reports no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31899540</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="doi">10.1002/mus.26801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2010;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RH Jr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harbor Perspect Med. 2018;8(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Cudkowicz ME, Berry JD, et al. A systematic review of enrichment strategies for current clinical trials. In: Proceedings from the ALS 29th International Symposium on ALS/MND; December 7&#x2010;9, 2018; Glasgow. United Kingdom..</Citation></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S, Aijo T, Vickovic S, et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science. 2019;364:89&#x2010;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, et al. Genome&#x2010;wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043&#x2010;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Gendron TF. Biomarkers for amyotrophic lateral sclerosis and frontotemporal dementia associated with hexanucleotide expansion mutations in C9orf72 . Front Neurol. 2018;9:1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289985</ArticleId><ArticleId IdType="pubmed">30568632</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, McKenna&#x2010;Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41:210&#x2010;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et al. Genome&#x2010;wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2010;1283. e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar UG, Milla V, Cynthia Stafford MY, Bjourson AJ, Duddy W, Duguez SM. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front Neurol. 2019;10:400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527847</ArticleId><ArticleId IdType="pubmed">31139131</ArticleId></ArticleIdList></Reference><Reference><Citation>Recabarren&#x2010;Leiva D, Alarcon M. New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci. 2018;193:110&#x2010;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">29241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Lobsiger CS, Boillee S. New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:764&#x2010;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">31306211</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. The PRO&#x2010;ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719&#x2010;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Nakamura R, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:230&#x2010;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Daghlas I, Lever TE, Leary E. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS&#x2010;R decline in ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:206&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">29260911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CT, Chiu YW, Wang KC, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long&#x2010;term and short&#x2010;term survival: a population&#x2010;based study of 1149 cases in Taiwan. J Epidemiol. 2013;23:35&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700231</ArticleId><ArticleId IdType="pubmed">23117224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Corcia P, Lacomblez L, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009;66:758&#x2010;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">19506136</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose&#x2010;ranging study. Lancet Neurol. 2018;17:416&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. The combined assessment of function and survival (cafs): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162&#x2010;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2010;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, Eijkemans MJ, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333&#x2010;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference><Reference><Citation>Taga A, Maragakis NJ. Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Rev Neurother. 2018;18:871&#x2010;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">30273061</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis. Biomark Med. 2018;12:693&#x2010;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">29856233</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP&#x2010;43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. BMC Neurol. 2018;18:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Goodall EF, Milo M, et al. Serum miRNAs miR&#x2010;206, 143&#x2010;3p and 374b&#x2010;5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 2017;55:123&#x2010;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Wyles M, Heath PR, et al. Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed mirnas related to neural and glial activity. Front Neurosci. 2017;11:731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry J, Aricha R, Kaspi H, et al. MicroRNA changes in the NurOwn phase 2 ALS randomized trial: relationship to neuroprotection and innate immunity. Presented at: The 17th Annual Northeast ALS Consortium Meeting; October 2&#x2010;4, 2018; Clearwater Beach. Florida..</Citation></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73:337&#x2010;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G, Leigh PN, Newbury SF, Hafezparast M. An overview of MicroRNAs as biomarkers of ALS. Front Neurol. 2019;10:186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E, Bremang M, Mitra V, et al. Combined tissue&#x2010;fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci Rep. 2019;9:4478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2016;3:866&#x2010;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP, Pooled Resource Open&#x2010;Access ALSCTC. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the Pooled Resource Open&#x2010;Access ALS Clinical Trials cohort. Muscle Nerve. 2018;57:937&#x2010;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">29244213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51&#x2010;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl SR, Kim RB, Coan GS, Mitchell CS. Unraveling the complexity of amyotrophic lateral sclerosis survival prediction. Front Neuroinform. 2018;12:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010549</ArticleId><ArticleId IdType="pubmed">29962944</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Taylor AA, Beaulieu D, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5:474&#x2010;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899911</ArticleId><ArticleId IdType="pubmed">29687024</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhao L, Tian L, et al. A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. Biometrics. 2016;72:877&#x2010;887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4916037</ArticleId><ArticleId IdType="pubmed">26689167</ArticleId></ArticleIdList></Reference><Reference><Citation>Beta&#x2010;Blocker Evaluation of Survival Trial I , Eichhorn EJ, Domanski MJ, Krause&#x2010;Steinrauf H, Bristow MR, Lavori PW. A trial of the beta&#x2010;blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659&#x2010;1667.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386264</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of efficacy and safety of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi F, Takei K, Tsuda K, Palumbo J. Post hoc analysis of MCI186&#x2010;17, the extension study to MCI186&#x2010;16, the confirmatory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:32&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872914</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well&#x2010;defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16:505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001&#x2010;a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Cudkowicz ME, Hardiman O, et al. VITALITY&#x2010;ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:259&#x2010;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">29402141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson KA, Cudkowicz ME, Berry JD. Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all? Neurotherapeutics. 2015;12:376&#x2010;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404442</ArticleId><ArticleId IdType="pubmed">25700798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, et al. Serum C&#x2010;reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74:660&#x2010;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Aricha R, Kaspi H, Cudkowicz M, et al. Modulation of CSF miRNAs in ALS phase 2 study participants treated with MSC&#x2010;NTF (NurOwn). Presented at: 70th Annual Meeting of the American Academy of Neurology; April 21&#x2010;27, 2018; Los Angeles. California..</Citation></Reference><Reference><Citation>Kovalchuk MO, Heuberger J, Sleutjes B, et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double&#x2010;blind, placebo&#x2010;controlled, crossover trial. Clin Pharmacol Ther. 2018;104:1136&#x2010;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">29672831</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn phase 2 randomized clinical trial in ALS: safety, clinical and biomarker results. Neurology. 2019;93(24):e2294&#x2010;e2305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, et al. TDP&#x2010;43 activates microglia through NF&#x2010;kappaB and NLRP3 inflammasome. Exp Neurol. 2015;273:24&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS&#x2010;R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:381&#x2010;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Thompson JL, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS&#x2010;R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2010;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo&#x2010;Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS&#x2010;R. Amyotroph Lateral Scler. 2010;11:178&#x2010;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Vaughan T, Wicks P, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808&#x2010;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390&#x2010;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol. 2018;75:58&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833488</ArticleId><ArticleId IdType="pubmed">29181534</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortis S, Corazalla EO, Wang Q, Kim HJ. The difference between slow and forced vital capacity increases with increasing body mass index: a paradoxical difference in low and normal body mass indices. Respir Care. 2015;60:113&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316893</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Liu D, Leitner ML, et al. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87:617&#x2010;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977369</ArticleId><ArticleId IdType="pubmed">27385750</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, Skerry LM, Munsat TL, et al. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012;45:81&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190312</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13:439&#x2010;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422377</ArticleId><ArticleId IdType="pubmed">22670883</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540&#x2010;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Transcranial magnetic stimulation for the assessment of neurodegenerative disease. Neurotherapeutics. 2017;14:91&#x2010;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233629</ArticleId><ArticleId IdType="pubmed">27830492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Kothalkar PV, Kim M, et al. Automatic prediction of intelligible speaking rate for individuals with ALS from speech acoustic and articulatory samples. Int J Speech Lang Pathol. 2018;20:669&#x2010;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506394</ArticleId><ArticleId IdType="pubmed">30409057</ArticleId></ArticleIdList></Reference><Reference><Citation>Grolez G, Moreau C, Danel&#x2010;Brunaud V, et al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. 2016;16:155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5002331</ArticleId><ArticleId IdType="pubmed">27567641</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonescu F, Adam M, Popa C, Tuta S. A review of cervical spine MRI in ALS patients. J Med Life. 2018;11:123&#x2010;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6101680</ArticleId><ArticleId IdType="pubmed">30140318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozik ME, Mitsumoto H, Brooks BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:406&#x2010;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">25125035</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly EJ, Liu D, Johns DR, et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:120&#x2010;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5531275</ArticleId><ArticleId IdType="pubmed">27677562</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Chataway T, Schultz DW, Rush RA, Rogers ML. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 2014;9:e87398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903651</ArticleId><ArticleId IdType="pubmed">24475283</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2010;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2010;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86:565&#x2010;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light chain NF&#x2010;L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND&#x2010;net. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:112&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">27819158</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89:239&#x2010;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al. Regulatory T&#x2010;lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64&#x2010;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Green C, Altschuler G, et al. A data&#x2010;driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2017;5:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5353945</ArticleId><ArticleId IdType="pubmed">28302159</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125:1767&#x2010;1779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463186</ArticleId><ArticleId IdType="pubmed">25932674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88:99&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>El Fatimy R, Li S, Chen Z, et al. MicroRNA&#x2010;132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136:537&#x2010;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132948</ArticleId><ArticleId IdType="pubmed">29982852</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Muller K, Ludolph AC, Weishaupt JH. Systemic dysregulation of TDP&#x2010;43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2013;1:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893596</ArticleId><ArticleId IdType="pubmed">24252274</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A, Zurolo E, Prabowo A, et al. MicroRNA&#x2010;146a: a key regulator of astrocyte&#x2010;mediated inflammatory response. PLoS One. 2012;7:e44789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441440</ArticleId><ArticleId IdType="pubmed">23028621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LF, Boldin MP, Chaudhry A, et al. Function of miR&#x2010;146a in controlling Treg cell&#x2010;mediated regulation of Th1 responses. Cell. 2010;142:914&#x2010;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049116</ArticleId><ArticleId IdType="pubmed">20850013</ArticleId></ArticleIdList></Reference><Reference><Citation>Saba R, Sorensen DL, Booth SA. MicroRNA&#x2010;146a: a dominant, negative regulator of the innate immune response. Front Immunol. 2014;5:578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240164</ArticleId><ArticleId IdType="pubmed">25484882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>